Microneedles Drug Delivery: Polymeric Microneedle Arrays: Versatile Tools for an Innovative Approach to Drug Administration (Adv. Therap. 8/2019)

Dardano, Principia; Battisti, Mario; Rea, Ilaria; Serpico, Luigia; Terracciano, Monica; Cammarano, Aniello; Nicolais, L.; Stefano, Luca De

doi:10.1002/adtp.201970018

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For CURATE.AI to be implemented in the clinical setting and practice, regulatory standards and qualifications must be satisfied similar to those applied to traditionally defined drugs and devices, with recent additions such as combina tion products [95][96][97] and now medical software. [98][99][100] To address the newly emergent field of medical software, the International Medical Device Regulatory Forum (IMDRF) and Food and Drug Administration (FDA) have broadly classified such software as Software as Medical Device (SaMD) and Clinical Decision Support Software (CDSS).…”

Section: Clinical Implementationmentioning

confidence: 99%

CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence

2020

View full text Add to dashboard Cite

The clinical team attending to a patient upon a diagnosis is faced with two main questions: what treatment, and at what dose? Clinical trials’ results provide the basis for guidance and support for official protocols that clinicians use to base their decisions upon. However, individuals rarely demonstrate the reported response from relevant clinical trials, often the average from a group representing a population or subpopulation. The decision complexity increases with combination treatments where drugs administered together can interact with each other, which is often the case. Additionally, the individual’s response to the treatment varies over time with the changes in his or her condition, whether via the indication or physiology. In practice, the drug and the dose selection depend greatly on the medical protocol of the healthcare provider and the medical team’s experience. As such, the results are inherently varied and often suboptimal. Big data approaches have emerged as an excellent decision-making support tool, but their application is limited by multiple challenges, the main one being the availability of sufficiently big datasets with good quality, representative information. An alternative approach—phenotypic personalized medicine (PPM)—finds an appropriate drug combination (quadratic phenotypic optimization platform [QPOP]) and an appropriate dosing strategy over time (CURATE.AI) based on small data collected exclusively from the treated individual. PPM-based approaches have demonstrated superior results over the current standard of care. The side effects are limited while the desired output is maximized, which directly translates into improving the length and quality of individuals’ lives.

show abstract

Section: Clinical Implementationmentioning

confidence: 99%

CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence

2020

View full text Add to dashboard Cite

show abstract

“…HMNs Fabrication: HMNs were fabricated by a one-shot fabrication process using a photolithography-based method. [32,44] HMNs were obtained using a photolithographic mask (JD Photo Data) containing an array of rings made of an outer transparent circle with a diameter of 750 μm and a dark inner circle of 500 μm. The centers of the two circles were not aligned and presented a center-to-center distance of 30 μm.…”

Section: Methodsmentioning

confidence: 99%

“…The HMNs arrays were fabricated using a photolithographic method by a one-shot fabrication process. [32,44] It is a versatile and low-cost method that allows the production of an array of HMNs with an asymmetric tip in a few seconds, with easily tuneable properties. 3D structures were defined by a chromium mask, consisting of a dark region with a transparent array of asymmetric rings (Figure 1a).…”

Section: Fabrication and Characterization Of Hmns Arraysmentioning

confidence: 99%

Hollow Microneedle‐based Plasmonic Sensor for on Patch Detection of Molecules in Dermal Interstitial Fluid

Miranda

Battisti²,

Martino³

et al. 2023

Adv Materials Technologies

Self Cite

View full text Add to dashboard Cite

Interstitial fluid (ISF) extraction and analysis are challenges that can be tackled by Hollow MicroNeedles (HMNs) technology, overcoming most of the difficulties associated with in situ detection. Herein, a plasmonic transducer, composed of gold nanoparticles embedded in poly(ethylene glycol) diacrylate (PEGDA) hydrogels, is integrated in the inner cavity of HMNs to detect biomarkers from the ISF‐based point‐of‐care. The wearable HMN‐based patch is used for minimally invasive pierce of the skin. The large swelling capability of the plasmonic transducer allows the uptake of ISF by capillarity. Biotin, as a small model molecule, is efficiently collected in the inner cavity of HMN and its high specificity with the streptavidin is exploited as a validation of the plasmonic nanocomposite functionality embedded within. The recognition of biotin is achieved in dual‐optical mode: the localized surface plasmon resonance (label‐free) and the metal‐enhanced fluorescence (label‐based). Overall, the proposed HMN‐based patch for target sensing in ISF can represent a novel point‐of‐use device for the detection of biomarkers as an alternative to conventional hospital or lab settings to help faster medical decision‐making.

show abstract

“…[28] Hollow microneedles have been fabricated from silicon, [51][52] polymers, [53] and metal, [54] due to the prominent malleability as well as robustness. Accurate microfabrication can form an inner cavity allowing an open channel of nanoparticles, [55] or filling with conducting materials for direct electrochemical sensing. [56] Jiang et al presented a microneedle-based skin patch for the rapid detection of protein biomarkers.…”

Section: Hollow Microneedlesmentioning

confidence: 99%

Wearable Clinic: From Microneedle‐Based Sensors to Next‐Generation Healthcare Platforms

Sun

Zheng

Shi

et al. 2023

Small

View full text Add to dashboard Cite

The rapid development of wearable biosensing calls for next‐generation devices that allow continuous, real‐time, and painless monitoring of health status along with responsive medical treatment. Microneedles have exhibited great potential for the direct access of dermal interstitial fluid (ISF) in a minimally invasive manner. Recent studies of microneedle‐based devices have evolved from conventional off‐line detection to multiplexed, wireless, and integrated sensing. In this review, the classification and fabrication techniques of microneedles are first introduced, and then the representative examples of microneedles for transdermal monitoring with different sensing modalities are summarized. State‐of‐the‐art advances in therapeutic and closed‐loop systems are presented to formulate guidelines for the development of next‐generation microneedle‐based healthcare platforms. The potential challenges and prospects are discussed to pave a new avenue toward pragmatic applications in the real world.

show abstract

Microneedles Drug Delivery: Polymeric Microneedle Arrays: Versatile Tools for an Innovative Approach to Drug Administration (Adv. Therap. 8/2019)

Cited by 3 publications

References 0 publications

CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence

CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence

Hollow Microneedle‐based Plasmonic Sensor for on Patch Detection of Molecules in Dermal Interstitial Fluid

Wearable Clinic: From Microneedle‐Based Sensors to Next‐Generation Healthcare Platforms

Contact Info

Product

Resources

About